Feedback / Questions
avutometinib (VS-6766) - Verastem
defactinib (VS-6063) - Verastem
https://www.businesswire.com/news/home/20240509453333/en/Verastem-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Business-Updates
May 9, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next